July 23, 2017 1:24 PM ET

Pharmaceuticals

Company Overview of Sandoz Inc.

Company Overview

Sandoz Inc. develops, manufactures, markets, and distributes generic pharmaceutical products. Its therapeutic drug categories include anti-infectives, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agents, oncology therapies, respiratory therapies, alimentary tract and metabolism, blood and blood-forming organs, and antineoplastic and immunomodulating agents. The company provides oral solid generics to advanced application forms, such as transdermal patches and implants; and complex products, such as follow-on biologics (biosimilars), injectables, and inhalables. It sells its products to small and large retailers, wholesalers, hospitals, prescription b...

100 College Road West

Princeton, NJ 08540

United States

Founded in 1946

Phone:

609-627-8500

Fax:

609-627-8659

Key Executives for Sandoz Inc.

President and Head of North America
Age: 53
President of Oriel Therapeutics
Vice President of Legal, IP & Compliance and General Counsel of NA
Head of Global Development Biopharmaceuticals & Oncology Injectables
Age: 64
Head of Biopharmaceuticals and Oncology Injectables
Compensation as of Fiscal Year 2017.

Sandoz Inc. Key Developments

Sandoz Inc. Wins $6.42 Million Federal Contract

Sandoz Inc. has won a $6,421,953.20 federal contract modification from the U.S. Department of Veterans Affairs for perphenazine tablets.

Sandoz Inc. Wins $13.85 Million Federal Contract

Sandoz Inc. won a $13,845,180 federal contract from the Defense Logistics Agency for rivastigmine patches.

Medicis Pharmaceutical Corp., Valeant Pharmaceuticals International, Inc., Impax Laboratories, Inc., Lupin Limited, Lupin Pharmaceuticals Inc., and Sandoz Inc. Partially Settle Class Action Lawsuit Involving the Antibiotic Drug Solodyn

Partial settlements have been reached in a class action lawsuit involving the antibiotic drug Solodyn. The lawsuit claims that Medicis Pharmaceutical Corp., Valeant Pharmaceuticals International, Inc., Impax Laboratories, Inc., Lupin Limited, Lupin Pharmaceuticals Inc., and Sandoz Inc. (Defendants) violated state competition (antitrust and consumer protection) and unjust enrichment laws by agreeing not to compete with each other and keeping lower-cost generic versions of Solodyn off the market. The Defendants deny this. No one is claiming that Solodyn is unsafe or ineffective. To settle the lawsuit, Lupin Pharmaceuticals Inc. and Lupin Limited (Lupin Defendants) and Sandoz Inc. have each agreed: that they would be willing to provide certain witnesses that Plaintiffs could call and a declaration that the Plaintiffs could use during the Solodyn case involving the overall End-Payor Class, other Plaintiffs, and the Non-Settling Defendants; and to deposit $625,000 and $1.75 million, respectively, into Settlement Funds. If the Settlements are approved by the Court and become final, the Settlement Funds, inclusive of interest, will be used to: pay for costs and expenses incurred or to be incurred by Counsel in continuing the lawsuit against Medicis Pharmaceutical Corp., Valeant Pharmaceuticals International, Inc., and Impax Laboratories, Inc. (Non-Settling Defendants); cover taxable costs and taxes payable on the Settlement Funds; pay for notice and other expenses; and pay for service awards not to exceed $10,000 to the class representatives in recognition of their efforts to date on behalf of the Classes. Any remainder in the Settlement Funds, after the payment of the above expenses, shall be distributed to the End-Payor Class for the Lupin Settlement and the End-Payor Class for the Sandoz Settlement in a manner approved by the court at the conclusion of the litigation. These settlements involve only the Lupin Defendants and Sandoz. The case will continue against the non-settling defendants.

Similar Private Companies By Industry

Company Name Region
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
December 15, 2016
Upsher-Smith Laboratories, Inc., AmLactin Family of Brands
Merger/Acquisition
October 18, 2016
Sandoz Inc., More Than 20 US Generic Products
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Sandoz Inc., please visit www.us.sandoz.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.